메뉴 건너뛰기




Volumn 116, Issue 7, 2010, Pages 1656-1663

Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction

Author keywords

Esophagus cancer; Gastroesophageal junction; Nonplatinum chemoradiotherapy regimen; Platinum; Trimodality therapy

Indexed keywords

DOCETAXEL; FLUOROURACIL; IRINOTECAN;

EID: 77950244862     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24935     Document Type: Article
Times cited : (16)

References (50)
  • 3
    • 51049091878 scopus 로고    scopus 로고
    • Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age
    • Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184-1187.
    • (2008) J Natl Cancer Inst , vol.100 , pp. 1184-1187
    • Brown, L.M.1    Devesa, S.S.2    Chow, W.H.3
  • 4
    • 13744258445 scopus 로고    scopus 로고
    • The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence
    • Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 142-146
    • Pohl, H.1    Welch, H.G.2
  • 5
    • 77950251601 scopus 로고    scopus 로고
    • Available at: Accessed October 14
    • Cancer Research UK. Oesophageal (gullet) cancer. Available at: http://info.cancerresearchuk.org/cancerstats/types/oesophagus/incidence/ Accessed October 14, 2008.
    • (2008) Oesophageal (Gullet) Cancer
  • 6
    • 0038048221 scopus 로고    scopus 로고
    • The national practice for patients receiving radiation therapy for carcinoma of the esophagus: Results of the 1996-1999 Patterns of Care Study
    • Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2003; 56:981-987.
    • (2003) Int J Radiat Oncol Biol Phys , vol.56 , pp. 981-987
    • Suntharalingam, M.1    Moughan, J.2    Coia, L.R.3
  • 7
    • 20244389414 scopus 로고    scopus 로고
    • Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus
    • Suntharalingam M, Moughan J, Coia LR, et al. Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol. 2005;23:2325-2331.
    • (2005) J Clin Oncol , vol.23 , pp. 2325-2331
    • Suntharalingam, M.1    Moughan, J.2    Coia, L.R.3
  • 8
    • 55549141865 scopus 로고    scopus 로고
    • Neoadjuvant chemoradiotherapy in esophageal cancer: Is it still the question?
    • Pereira B, Gourgou-Bourgade S, Azria D, Ychou M. Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question? J Clin Oncol. 2008;26:5133-5134.
    • (2008) J Clin Oncol , vol.26 , pp. 5133-5134
    • Pereira, B.1    Gourgou-Bourgade, S.2    Azria, D.3    Ychou, M.4
  • 9
    • 41949119177 scopus 로고    scopus 로고
    • Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781
    • Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
    • (2008) J Clin Oncol , vol.26 , pp. 1086-1092
    • Tepper, J.1    Krasna, M.J.2    Niedzwiecki, D.3
  • 10
    • 0035863382 scopus 로고    scopus 로고
    • Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma
    • Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
    • (2001) J Clin Oncol , vol.19 , pp. 305-313
    • Urba, S.G.1    Orringer, M.B.2    Turrisi, A.3    Iannettoni, M.4    Forastiere, A.5    Strawderman, M.6
  • 11
    • 0030793423 scopus 로고    scopus 로고
    • Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
    • Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
    • (1997) N Engl J Med , vol.337 , pp. 161-167
    • Bosset, J.F.1    Gignoux, M.2    Triboulet, J.P.3
  • 13
    • 0033526355 scopus 로고    scopus 로고
    • Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group
    • Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623-1627.
    • (1999) JAMA , vol.281 , pp. 1623-1627
    • Cooper, J.S.1    Guo, M.D.2    Herskovic, A.3
  • 14
    • 20144362218 scopus 로고    scopus 로고
    • Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
    • Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
    • (2005) Cancer , vol.103 , pp. 1347-1355
    • Chirieac, L.R.1    Swisher, S.G.2    Ajani, J.A.3
  • 15
    • 28044442478 scopus 로고    scopus 로고
    • Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response
    • Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005;104:2365-2372.
    • (2005) Cancer , vol.104 , pp. 2365-2372
    • Rohatgi, P.1    Swisher, S.G.2    Correa, A.M.3
  • 16
    • 22344446070 scopus 로고    scopus 로고
    • Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival
    • Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337.
    • (2005) J Clin Oncol , vol.23 , pp. 4330-4337
    • Berger, A.C.1    Farma, J.2    Scott, W.J.3
  • 17
    • 33947534209 scopus 로고    scopus 로고
    • American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma
    • Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507-512.
    • (2007) J Clin Oncol , vol.25 , pp. 507-512
    • Rizk, N.P.1    Venkatraman, E.2    Bains, M.S.3
  • 18
    • 47049083743 scopus 로고    scopus 로고
    • Therapy of localized esophageal cancer: It is time to reengineer our investigative strategies
    • Ajani J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie. 2008; 31:360-361.
    • (2008) Onkologie , vol.31 , pp. 360-361
    • Ajani, J.1
  • 20
    • 0042887575 scopus 로고    scopus 로고
    • Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer
    • Ilson DH, Bains M, Kelsen DP, et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003;21:2926-2932.
    • (2003) J Clin Oncol , vol.21 , pp. 2926-2932
    • Ilson, D.H.1    Bains, M.2    Kelsen, D.P.3
  • 21
    • 4043057156 scopus 로고    scopus 로고
    • Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy
    • Brenner B, Ilson DH, Minsky BD, et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 2004; 22:45-52.
    • (2004) J Clin Oncol , vol.22 , pp. 45-52
    • Brenner, B.1    Ilson, D.H.2    Minsky, B.D.3
  • 22
    • 0642337685 scopus 로고    scopus 로고
    • Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial
    • Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003;9:251-260.
    • (2003) Cancer J , vol.9 , pp. 251-260
    • Meluch, A.A.1    Greco, F.A.2    Gray, J.R.3
  • 23
    • 0035424614 scopus 로고    scopus 로고
    • Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: Results of a Phase II trial
    • Hainsworth JD, Burris HA III, Meluch AA, Baker MN, Morrissey LH, Greco FA. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer. 2001;92:642-649.
    • (2001) Cancer , vol.92 , pp. 642-649
    • Hainsworth, J.D.1    Burris III, H.A.2    Meluch, A.A.3    Baker, M.N.4    Morrissey, L.H.5    Greco, F.A.6
  • 24
    • 0035117166 scopus 로고    scopus 로고
    • Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction
    • Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001;24:91-95.
    • (2001) Am J Clin Oncol , vol.24 , pp. 91-95
    • Schnirer, I.I.1    Komaki, R.2    Yao, J.C.3
  • 25
    • 47049108166 scopus 로고    scopus 로고
    • Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus
    • Javeri H, Arora R, Correa AM, et al. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008;113:1302-1308.
    • (2008) Cancer , vol.113 , pp. 1302-1308
    • Javeri, H.1    Arora, R.2    Correa, A.M.3
  • 26
    • 34548692964 scopus 로고    scopus 로고
    • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer
    • Kelsey CR, Chino JP, Willett CG, et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys. 2007; 69:770-776.
    • (2007) Int J Radiat Oncol Biol Phys , vol.69 , pp. 770-776
    • Kelsey, C.R.1    Chino, J.P.2    Willett, C.G.3
  • 27
    • 47049120242 scopus 로고    scopus 로고
    • Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of 2 phase II trials with longterm follow-up
    • Bader FG, Lordick F, Fink U, et al. Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of 2 phase II trials with longterm follow-up. Onkologie. 2008;31:366-372.
    • (2008) Onkologie , vol.31 , pp. 366-372
    • Bader, F.G.1    Lordick, F.2    Fink, U.3
  • 28
    • 58149353001 scopus 로고    scopus 로고
    • Chemotherapy and radiotherapy resistance: Complexity, reality, and promise
    • author reply 163
    • Ajani JA, Izzo JG, Lee JS. Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol. 2009;27:162-163, author reply 163.
    • (2009) J Clin Oncol , vol.27 , pp. 162-163
    • Ajani, J.A.1    Izzo, J.G.2    Lee, J.S.3
  • 29
    • 0035878633 scopus 로고    scopus 로고
    • A 3-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction
    • Ajani JA, Komaki R, Putnam JB, et al. A 3-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001; 92:279-286.
    • (2001) Cancer , vol.92 , pp. 279-286
    • Ajani, J.A.1    Komaki, R.2    Putnam, J.B.3
  • 30
    • 20044366529 scopus 로고    scopus 로고
    • Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome
    • Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237-1244.
    • (2005) J Clin Oncol , vol.23 , pp. 1237-1244
    • Ajani, J.A.1    Mansfield, P.F.2    Crane, Ch.3
  • 31
    • 4344654904 scopus 로고    scopus 로고
    • Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma
    • Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004; 22:2774-2780.
    • (2004) J Clin Oncol , vol.22 , pp. 2774-2780
    • Ajani, J.A.1    Mansfield, P.F.2    Janjan, N.3
  • 32
    • 33748462703 scopus 로고    scopus 로고
    • Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response
    • Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953-3958.
    • (2006) J Clin Oncol , vol.24 , pp. 3953-3958
    • Ajani, J.A.1    Winter, K.2    Okawara, G.S.3
  • 33
    • 33845953627 scopus 로고    scopus 로고
    • Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome
    • Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31:58-64.
    • (2007) Am J Surg Pathol , vol.31 , pp. 58-64
    • Wu, T.T.1    Chirieac, L.R.2    Abraham, S.C.3
  • 34
    • 0024202761 scopus 로고
    • Sample size considerations for studies comparing survival curves using historical controls
    • Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol. 1988;41:1209-1213.
    • (1988) J Clin Epidemiol , vol.41 , pp. 1209-1213
    • Dixon, D.O.1    Simon, R.2
  • 35
    • 53749102232 scopus 로고    scopus 로고
    • Phase II randomized trial of 2 nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113
    • Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of 2 nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008; 26:4551-4556.
    • (2008) J Clin Oncol , vol.26 , pp. 4551-4556
    • Ajani, J.A.1    Winter, K.2    Komaki, R.3
  • 36
    • 58549097877 scopus 로고    scopus 로고
    • Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer
    • author reply 468-469
    • Adenis A, Conroy T. Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer. J Clin Oncol. 2009;27:467-468, author reply 468-469.
    • (2009) J Clin Oncol , vol.27 , pp. 467-468
    • Adenis, A.1    Conroy, T.2
  • 37
    • 24944553737 scopus 로고    scopus 로고
    • Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d''Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study
    • Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d''Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910-5917.
    • (2005) J Clin Oncol , vol.23 , pp. 5910-5917
    • Fournel, P.1    Robinet, G.2    Thomas, P.3
  • 38
    • 24044509153 scopus 로고    scopus 로고
    • Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial
    • Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659-668.
    • (2005) Lancet Oncol , vol.6 , pp. 659-668
    • Burmeister, B.H.1    Smithers, B.M.2    Gebski, V.3
  • 39
    • 60849118127 scopus 로고    scopus 로고
    • Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction
    • Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-856.
    • (2009) J Clin Oncol , vol.27 , pp. 851-856
    • Stahl, M.1    Walz, M.K.2    Stuschke, M.3
  • 40
    • 52949133039 scopus 로고    scopus 로고
    • Cetuximab with concurrent chemoradiation for esophagogastric cancer: In regard to Safran, et al. (Int J Radiat Oncol Biol Phys. 2008;70:391-395)
    • Adenis A, Mariette C, Mirabel X, Seitz JF, Conroy T. Cetuximab with concurrent chemoradiation for esophagogastric cancer: in regard to Safran, et al. (Int J Radiat Oncol Biol Phys. 2008;70:391-395). Int J Radiat Oncol Biol Phys. 2008;72:958-959.
    • (2008) Int J Radiat Oncol Biol Phys , vol.72 , pp. 958-959
    • Adenis, A.1    Mariette, C.2    Mirabel, X.3    Seitz, J.F.4    Conroy, T.5
  • 41
    • 34347393724 scopus 로고    scopus 로고
    • Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
    • Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007;298:70-82.
    • (2007) JAMA , vol.298 , pp. 70-82
    • Karamouzis, M.V.1    Grandis, J.R.2    Argiris, A.3
  • 42
    • 26444557983 scopus 로고    scopus 로고
    • Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma
    • Hong D, Lunagomez S, Kim EE, et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005;104:1620-1626.
    • (2005) Cancer , vol.104 , pp. 1620-1626
    • Hong, D.1    Lunagomez, S.2    Kim, E.E.3
  • 43
    • 33750452675 scopus 로고    scopus 로고
    • The importance of PET in the diagnosis and response evaluation of esophageal cancer
    • Ott K, Weber W, Siewert JR. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus. 2006;19:433-442.
    • (2006) Dis Esophagus , vol.19 , pp. 433-442
    • Ott, K.1    Weber, W.2    Siewert, J.R.3
  • 44
    • 34249113173 scopus 로고    scopus 로고
    • PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer
    • Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-883.
    • (2007) Eur J Nucl Med Mol Imaging , vol.34 , pp. 878-883
    • Wieder, H.A.1    Geinitz, H.2    Rosenberg, R.3
  • 45
    • 36749006570 scopus 로고    scopus 로고
    • Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    • Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925-1932.
    • (2007) Eur J Nucl Med Mol Imaging , vol.34 , pp. 1925-1932
    • Wieder, H.A.1    Ott, K.2    Lordick, F.3
  • 46
    • 0034666024 scopus 로고    scopus 로고
    • Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma
    • Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18: 3202-3210.
    • (2000) J Clin Oncol , vol.18 , pp. 3202-3210
    • Flamen, P.1    Lerut, A.2    Van Cutsem, E.3
  • 47
    • 33947592259 scopus 로고    scopus 로고
    • PET/CT in cancer patient management. Commentary
    • Shankar LK, Sullivan DC. PET/CT in cancer patient management. Commentary. J Nucl Med. 2007;48(suppl 1): 1S.
    • (2007) J Nucl Med , vol.48 , Issue.SUPPL. 1
    • Shankar, L.K.1    Sullivan, D.C.2
  • 48
    • 34548185461 scopus 로고    scopus 로고
    • PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial
    • Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
    • (2007) Lancet Oncol , vol.8 , pp. 797-805
    • Lordick, F.1    Ott, K.2    Krause, B.J.3
  • 49
    • 53049095653 scopus 로고    scopus 로고
    • Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation
    • author reply 1196
    • Ajani JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer. 2008;99:1195, author reply 1196.
    • (2008) Br J Cancer , vol.99 , pp. 1195
    • Ajani, J.A.1
  • 50
    • 33644853585 scopus 로고    scopus 로고
    • Association of activated transcription factor nuclear factor kappa b with chemoradiation resistance and poor outcome in esophageal carcinoma
    • Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappa b with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748-754.
    • (2006) J Clin Oncol , vol.24 , pp. 748-754
    • Izzo, J.G.1    Malhotra, U.2    Wu, T.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.